ES2891088T3 - Métodos de diagnóstico, agentes terapéuticos y usos de los mismos - Google Patents
Métodos de diagnóstico, agentes terapéuticos y usos de los mismos Download PDFInfo
- Publication number
- ES2891088T3 ES2891088T3 ES17751177T ES17751177T ES2891088T3 ES 2891088 T3 ES2891088 T3 ES 2891088T3 ES 17751177 T ES17751177 T ES 17751177T ES 17751177 T ES17751177 T ES 17751177T ES 2891088 T3 ES2891088 T3 ES 2891088T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- subject
- level
- salt
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KXONJPJIFNGMCN-UHFFFAOYSA-O CC(C(N(CCC1)C1C(O)=O)=O)[N+](C)(C)C Chemical compound CC(C(N(CCC1)C1C(O)=O)=O)[N+](C)(C)C KXONJPJIFNGMCN-UHFFFAOYSA-O 0.000 description 1
- KXONJPJIFNGMCN-UHFFFAOYSA-N CC(C(N(CCC1)C1C([O-])=O)=O)[N+](C)(C)C Chemical compound CC(C(N(CCC1)C1C([O-])=O)=O)[N+](C)(C)C KXONJPJIFNGMCN-UHFFFAOYSA-N 0.000 description 1
- KXONJPJIFNGMCN-IENPIDJESA-O C[C@@H](C(N(CCC1)C1C(O)=O)=O)[N+](C)(C)C Chemical compound C[C@@H](C(N(CCC1)C1C(O)=O)=O)[N+](C)(C)C KXONJPJIFNGMCN-IENPIDJESA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367839P | 2016-07-28 | 2016-07-28 | |
| PCT/US2017/044151 WO2018022866A1 (en) | 2016-07-28 | 2017-07-27 | Diagnostic methods, therapeutic agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2891088T3 true ES2891088T3 (es) | 2022-01-26 |
Family
ID=59579921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17751177T Active ES2891088T3 (es) | 2016-07-28 | 2017-07-27 | Métodos de diagnóstico, agentes terapéuticos y usos de los mismos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10865183B2 (https=) |
| EP (1) | EP3491004B1 (https=) |
| JP (1) | JP6987123B2 (https=) |
| CN (1) | CN109563127B (https=) |
| AU (1) | AU2017301949B2 (https=) |
| CA (1) | CA3032116A1 (https=) |
| ES (1) | ES2891088T3 (https=) |
| WO (1) | WO2018022866A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184836A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| US11182920B2 (en) * | 2018-04-26 | 2021-11-23 | Jerry NAM | Automated determination of muscle mass from images |
| TWI669506B (zh) * | 2018-07-06 | 2019-08-21 | 國軍桃園總醫院 | 計算腎絲球過濾率之方法 |
| US12553902B2 (en) * | 2019-12-16 | 2026-02-17 | Hill's Pet Nutrition, Inc. | Methods, kits and compositions for diagnosing and treating renal disease |
| CN114026427B (zh) * | 2020-05-19 | 2023-11-17 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| WO2022125056A1 (en) | 2020-12-07 | 2022-06-16 | Kimberly-Clark Worldwide, Inc. | Methods and consumer products for detecting a metabolite |
| CN119355249A (zh) * | 2024-09-20 | 2025-01-24 | 长沙都正生物科技股份有限公司 | 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184836A1 (en) | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| US10393749B2 (en) * | 2013-12-11 | 2019-08-27 | Shiseido Company, Ltd. | Marker for early diagnosis of kidney failure |
-
2017
- 2017-07-27 AU AU2017301949A patent/AU2017301949B2/en active Active
- 2017-07-27 EP EP17751177.1A patent/EP3491004B1/en active Active
- 2017-07-27 CN CN201780046847.5A patent/CN109563127B/zh active Active
- 2017-07-27 WO PCT/US2017/044151 patent/WO2018022866A1/en not_active Ceased
- 2017-07-27 US US16/321,135 patent/US10865183B2/en active Active
- 2017-07-27 JP JP2019503956A patent/JP6987123B2/ja active Active
- 2017-07-27 CA CA3032116A patent/CA3032116A1/en active Pending
- 2017-07-27 ES ES17751177T patent/ES2891088T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3032116A1 (en) | 2018-02-01 |
| CN109563127B (zh) | 2024-01-05 |
| US20190152907A1 (en) | 2019-05-23 |
| JP6987123B2 (ja) | 2021-12-22 |
| US10865183B2 (en) | 2020-12-15 |
| CN109563127A (zh) | 2019-04-02 |
| EP3491004A1 (en) | 2019-06-05 |
| JP2019531261A (ja) | 2019-10-31 |
| AU2017301949B2 (en) | 2021-09-23 |
| WO2018022866A1 (en) | 2018-02-01 |
| AU2017301949A1 (en) | 2019-01-31 |
| EP3491004B1 (en) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2891088T3 (es) | Métodos de diagnóstico, agentes terapéuticos y usos de los mismos | |
| Sharma et al. | Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity | |
| ES2799327T3 (es) | Método para diagnosticar asfixia | |
| JP7424593B2 (ja) | エルゴチオネイン、ｓ－メチル－エルゴチオネイン、及びそれらの使用 | |
| ES2870851T3 (es) | Método para detectar enfermedades musculares degenerativas y método para determinar la eficacia terapéutica sobre las enfermedades | |
| ES2353835T3 (es) | Biomarcadores para evaluar la función hepática. | |
| JP2022091828A (ja) | 併用抗がん剤の感受性の判定マーカー | |
| US9958447B2 (en) | Immunoassay of S-adenosylmethionine in personalized medicine and health or cancer evaluation | |
| Dong et al. | Effects of patent foramen ovale in migraine: a metabolomics‐based study | |
| US11680042B2 (en) | Compounds, reagents, and uses thereof | |
| Cao et al. | Revealing the elevated sulfite levels in acute kidney injury using a promising ratiometric fluorescent probe | |
| WO2012007531A2 (en) | Methods and compositions for diagnosing medical conditions | |
| Smerikarova et al. | A brief review of analytical methods for the estimation of ttr kinetic stabilizers in pharmaceutical formulations and biological matrices | |
| TWI839361B (zh) | 腎病變小分子生物標記及其應用 | |
| JP7203391B2 (ja) | イリノテカンを含む抗がん剤療法の感受性判定マーカー | |
| ES2877365T3 (es) | Lípidos oxidados en el tratamiento de dolor crónico o neuropático | |
| ES2534732B1 (es) | Método de clasificación, diagnóstico y seguimiento de individuos con riesgo de padecer cáncer de pulmón mediante el análisis de sudor | |
| US10983137B2 (en) | Diagnosis of leukocyte-mediated disease and halogen gas exposure | |
| Parry et al. | Early Markers of Cardiac and Skeletal Muscle Metabolic Derangement in the Apc (min/+) Male Mouse | |
| CA3059264A1 (en) | Oxidized lipids as biomarkers for neuropathic pain | |
| JPWO2019098351A1 (ja) | 糖尿病合併症用マーカー | |
| JP2021185378A (ja) | 標的分子を検出する非侵襲的方法 | |
| WO2020067228A1 (ja) | 併用抗がん剤の感受性の判定マーカー |